IGC To Enter California Market With Hyalolex

MARYLAND: India Globalization Capital (IGC) has designated California as a priority market for Hyalolex, its lead cannabis-based supplement for treating and managing Alzheimer’s patients.

“The cannabis market is showing explosive growth and we are aggressively moving forward with our vision of owning and marketing the leading brands for large medical indications such as Alzheimer’s, Parkinson’s, PTSD, pain, veterinary medicine and cancer. With 8 patents filed, IGC has made significant strides towards achieving these goals and building value for our shareholders as a NYSE American listed company,” stated Ram Mukunda, CEO of IGC.

“California is considered to be the largest addressable U.S. market for cannabis with an environment that strongly embraces its acceptance. This represents a significant opportunity for Hyalolex and our brands, as such we are currently coordinating the necessary steps to efficiently and rapidly introduce our product to high-density regions in the state. It should be noted that according to U.S. Census data, California has an estimated population of 39.54 million and that total is larger than all of Canada,” continued Mukunda.

IGC’s management team has been actively meeting with California-based manufacturers and distributers to assemble the requisite combination of partners to efficiently bring Hyalolex to dispensaries, patients and caregivers in California. Our “Drops of Clarity” marketing program will highlight the potential benefits of Hyalolex as a supplement to cannabis physicians as well as to caregivers and patients via both a digital format and through grassroots outreach.

Puerto Rican Alzheimer’s Patients To Be First In U.S. To Obtain Cannabis-Based Relief

MARYLAND: Alzheimer’s patients in Puerto Rico will be the first in the United States to obtain Hyalolex, IGC’s proprietary cannabinoid based formulation aimed at relieving many of the symptoms of Alzheimer’s Disease, such as agitation, anxiety, sleep disorder, as well as caregiver distress, among others.

Pursuant to an agreement between IGC and DaMa Pharmaceutical and its affiliates, Hyalolex will be on the shelves in April, and available to patients in ten of Puerto Rico’s 30 dispensaries, including the two premier dispensaries in San Juan, the largest city in Puerto Rico. Under the licensing terms DaMa will help produce Hyalolex in Puerto Rico, and market Hyalolex to medical dispensaries and end users. Hyalolex will be prescribed as a liquid supplement in twice-daily doses for mild to moderate Alzheimer patients, and thrice-daily doses for moderate to advanced patients.

“We are very pleased to work with the DaMa Pharmaceutical team to bring Hyalolex to Puerto Rico, which has a long history of developing premier pharmaceutical products,” said Ram Mukunda CEO of IGC. He noted that the Puerto Rican government has been a supporter of a comprehensive medical cannabis program. “We are proud to be a contributor to Puerto Rico’s economic development and to the wellbeing of its Alzheimer’s patients”, he said. According to alz.org, Hispanics are approximately one and one-half times as likely to have Alzheimer’s as non-Hispanic whites.

“This is a decisive step in delivering our cannabis intellectual property to patients, after many years of development. It is particularly important as part of our effort to establish a distribution network to productize our IP,” Mukunda said.

This partnership represents a significant opportunity to provide those afflicted with Alzheimer’s with potential relief from a very difficult diagnosis and ease the burden of their caregivers who attend to them. It also represents a significant opportunity to collect data on Hyalolex’s performance within a diverse patient set”, said Mukunda. IGC will deploy a QR code-based product assurance, information dissemination, and data collection system as a step towards a more robust block chain-based product assurance system.